ganglioside--gd1a and Nerve-Degeneration

The present study evaluated the neurotoxicity of various gangliosides against dopaminergic neurons in mesencephalic cultures. Among them, GD1a and GD1b but not GD3 and GQ1b were found to be neurotoxic against dopaminergic neurons as determined by TH immunocytochemistry and [(3)H]DA uptake. When quantified and expressed as a percentage of control values, treatment with 60-200 microg/ml GD1a and GD1b attenuated the number of TH-ip neurons by 31-47% and 37-55%, respectively, compared with non-treated control cultures. Consistent with the results of the TH immunocytochemistry, treatment with 60-200 microg/ml GD1a and GD1b reduced [(3)H]DA uptake levels by 27-56% and 41-60%, respectively, compared with non-treated control cultures. This neurotoxicity was almost completely abolished in the presence of neuraminidase, which removes the sialic acid residues from ganglioside, or in the treatment of insulin or IGF-1. Additional immunostaining also showed a significant loss of GABAergic neurons in GD1a or GD1b-treated cultures, indicating non-selective neurotoxicity of GD1a and GD1b. Moreover, these gangliosides had little effect on nitric oxide (NO) production in mesencephalic or microglia cultures. Together, these data suggest that GD1a and GD1b exert a direct neurotoxicity against dopaminergic neurons independent of NO and/or microglia.

Topics: Animals; Cell Death; Cells, Cultured; Dopamine; Gangliosides; Insulin; Insulin-Like Growth Factor I; Mesencephalon; Microglia; N-Acetylneuraminic Acid; Nerve Degeneration; Neuraminidase; Neurons; Nitric Oxide; Rats; Rats, Sprague-Dawley

Immune responses against gangliosides are strongly implicated in the pathogenesis of some variants of Guillain-Barré syndrome (GBS). For example, IgG antibodies against GM1, GD1a, and related gangliosides are frequently present in patients with post-Campylobacter acute motor axonal neuropathy (AMAN) variant of GBS, and immunization of rabbits with GM1 has produced a model of AMAN. However, the role of anti-ganglioside antibodies in GBS continues to be debated because of lack of a passive transfer model. We recently have raised several monoclonal IgG anti-ganglioside antibodies. We passively transfer these antibodies by intraperitoneal hybridoma implantation and by systemic administration of purified anti-ganglioside antibodies in mice. Approximately half the animals implanted with an intraperitoneal clone of anti-ganglioside antibody-secreting hybridoma developed a patchy, predominantly axonal neuropathy affecting a small proportion of nerve fibers. In contrast to hybridoma implantation, passive transfer with systemically administered anti-ganglioside antibodies did not cause nerve fiber degeneration despite high titre circulating antibodies. Blood-nerve barrier studies indicate that animals implanted with hybridoma had leaky blood-nerve barrier compared to mice that received systemically administered anti-ganglioside antibodies. Our findings suggest that in addition to circulating antibodies, factors such as antibody accessibility and nerve fiber resistance to antibody-mediated injury play a role in the development of neuropathy.

Topics: Animals; Antibodies, Monoclonal; Antibody Formation; Blood-Brain Barrier; Blotting, Western; Capillary Permeability; Disease Models, Animal; G(M1) Ganglioside; Gangliosides; Hybridomas; Immunoglobulin G; Immunohistochemistry; Ki-67 Antigen; Male; Mice; Mice, Inbred Strains; Nerve Degeneration; Peripheral Nerves; Peripheral Nervous System Diseases; Species Specificity; Spinal Cord

We report cases of 2 patients with pure motor Guillain-Barré syndrome of explosive onset who required mechanical ventilation for more than 2 months. Their electrophysiologic findings and poor clinical recoveries suggested severe axonal degeneration involving the motor nerves. Enzyme-linked immunosorbent assay and thin-layer chromatogram-immunostaining showed the sera of both patients had high IgG antibody titer against GD1a ganglioside. Their titers decreased with the clinical course of the illness. GD1a as well as GM1, appears to be the target pathogenic antigen in motor axon disorders. Elevated IgG anti-GD1a antibody titer may prove useful for predicting severe GBS.

Topics: Acute Disease; Adult; Axons; Campylobacter Infections; Campylobacter jejuni; Chromatography, Thin Layer; Enzyme-Linked Immunosorbent Assay; Gangliosides; Humans; Immunoglobulin G; Male; Nerve Degeneration; Neural Conduction; Polyradiculoneuropathy